[go: up one dir, main page]

NZ747129B2 - Use of probiotics in the treatment and/or prevention of psoriasis - Google Patents

Use of probiotics in the treatment and/or prevention of psoriasis

Info

Publication number
NZ747129B2
NZ747129B2 NZ747129A NZ74712917A NZ747129B2 NZ 747129 B2 NZ747129 B2 NZ 747129B2 NZ 747129 A NZ747129 A NZ 747129A NZ 74712917 A NZ74712917 A NZ 74712917A NZ 747129 B2 NZ747129 B2 NZ 747129B2
Authority
NZ
New Zealand
Prior art keywords
psoriasis
prevention
treatment
composition
outbreaks
Prior art date
Application number
NZ747129A
Other versions
NZ747129A (en
Inventor
Cuadros Maria Empar Chenoll
Cortes Francisco Manuel Codoner
Martinez Salvador Genoves
Lopez Vicente Manuel Navarro
Orquin Jose Manuel Perez
Bosca Ana Adela Ramirez
Vidal Daniel Ramon
Original Assignee
Bionou Research Sl
Biopolis SL
Filing date
Publication date
Priority claimed from EP16382122.6A external-priority patent/EP3222282A1/en
Application filed by Bionou Research Sl, Biopolis SL filed Critical Bionou Research Sl
Publication of NZ747129A publication Critical patent/NZ747129A/en
Publication of NZ747129B2 publication Critical patent/NZ747129B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

The present invention is intended for the use of a probiotic composition comprising Bifidobacterium animalis subs, lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, in particular the strains B. lactis CECT 8145, B. longum ES1 CECT 7347 and/or L. rhamnosus CECT 8361, in the treatment and/or prevention of psoriasis outbreaks or psoriasis.

Claims (14)

1. A probiotic composition comprising Bifidobacterium animalis subsp. lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis, wherein B. lactis is B. lactis CECT 8145, B. longum is B. longum ES1 CECT 7347 and L. rhamnosus is L. rhamnosus CECT 8361.
2. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 1, wherein the psoriasis outbreak or psoriasis is selected from the group consisting of plaque psoriasis, palmar-plantar psoriasis, scalp psoriasis, nail psoriasis, psoriasis on the face, psoriasis in the folds, guttate psoriasis, erythrodermic psoriasis and pustular psoriasis.
3. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 1 or 2, wherein the probiotic composition is a pharmaceutical composition or a nutritional composition.
4. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 3, wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier and/or an excipient.
5. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 3 or 4, wherein the pharmaceutical composition is formulated for administration in liquid form or in solid form.
6. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 5, wherein the solid formulation is selected from the group consisting of tablets, lozenges, sweets, chewable tablets, chewing gum, capsules, sachets, powders, granules, coated particles or coated tablets, tablets and gastro-resistant tablets and capsules and dispersible strips and films.
7. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 5, wherein the liquid formulation is selected from the group consisting of oral solutions, suspensions, emulsions and syrups.
8. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 3, wherein the nutritional composition is a food or a nutritional supplement.
9. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 8, wherein the food is selected from the group consisting of fruit or vegetable juices, ice cream, infant formula, milk, yogurt, cheese, fermented milk, milk powder, cereals, baked goods, milk-based products, meat products and beverages.
10. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to any one of claims 1 to 9, wherein the composition further comprises a microorganism selected from the group consisting of Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Saccharomyces sp., Kluyveromyces sp. and combinations thereof.
11. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to any one of claims 1 to 10, wherein the total concentration of microorganisms of the strains B. lactis, L. rhamnosus and B. longum in the composition is between 10 and 10 cfu.
12. The probiotic composition for use in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis according to claim 11, wherein the total concentration of microorganisms of the strains B. lactis, L. rhamnosus and B. longum in the composition is 10 cfu.
13. A probiotic composition comprising microorganisms of Bifidobacterium animalis subs. lactis (B. lactis), Bifidobacterium longum and Lactobacillus rhamnosus, wherein the concentration of B. longum with respect to the total concentration of microorganisms present in the composition is at least 30%, and wherein B. lactis is B. lactis CECT 8145, B. longum is B. longum ES1 CECT 7347 and L. rhamnosus is L. rhamnosus CECT 8361.
14. The probiotic composition according to claim 13, for use as a medicament in the treatment and/or prevention of psoriasis outbreaks and/or psoriasis.
NZ747129A 2017-03-21 Use of probiotics in the treatment and/or prevention of psoriasis NZ747129B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382122.6A EP3222282A1 (en) 2016-03-21 2016-03-21 Use of probiotics in the treatment and/or prevention of psoriasis
PCT/EP2017/056719 WO2017162683A1 (en) 2016-03-21 2017-03-21 Use of probiotics in the treatment and/or prevention of psoriasis

Publications (2)

Publication Number Publication Date
NZ747129A NZ747129A (en) 2025-02-28
NZ747129B2 true NZ747129B2 (en) 2025-06-04

Family

ID=

Similar Documents

Publication Publication Date Title
RU2018136939A (en) APPLICATION OF PROBIOTICS FOR THE TREATMENT AND / OR PREVENTION OF PSORIASIS
RU2019104462A (en) APPLICATION OF PROBIOTICS IN THE TREATMENT AND / OR PREVENTION OF ATOPIC DERMATITIS
De Vrese et al. Probiotics, prebiotics, and synbiotics
EP2990045B1 (en) Bifidobacterium animalis subsp. lactis for use in decreasing abdominal pain in a postmenopausal woman
CA2477144A1 (en) Orally administrable composition for the photoprotection of the skin
RU2004128078A (en) LIGHT PROTECTED FOR ORAL RECEPTION COMPOSITION FOR SKIN
SI3048165T1 (en) Novel strain of bifidobacterium animalis subsp. lactis cect 8145 and use thereof for the treatment and/or prevention of excess weight and obesity and associated diseases
CN101626774A (en) Composition for improving intestinal microflora
US11554096B2 (en) Probiotics-delivering hydrogel formulation for protecting probiotics in acidic environment and composition for delivering probiotics comprising same
JPWO2017130859A1 (en) Nerve cell death inhibitor
WO2021256476A1 (en) Method for improving resistance of lactic acid bacteria to gastric juices/bile
JP2019116423A (en) Composition for intestinal regulation
HRP20250886T1 (en) POSTBIOTICS PREPARATIONS CONTAINING B. LONGUM CECT-7347 AND L. RHAMNOSUS CECT-8361 AND THEIR THERAPEUTIC USE
Lokhande et al. A systematic study of probiotics-an update review
Witzler et al. Development of a potential probiotic lozenge containing Enterococcus faecium CRL 183
JP2018177703A (en) Toll-like receptor 2 activating composition
Stabnikov et al. Recent advances in the study of the properties and applications of lactic acid bacteria
JPWO2020116511A1 (en) Composition for suppressing norovirus infection
CN103037877A (en) Agent for controlling the increase and decrease of lactobacillus bifidus in colon
NZ747129B2 (en) Use of probiotics in the treatment and/or prevention of psoriasis
JP6918465B2 (en) Composition for suppressing reduction of lactic acid bacteria of the genus Lactobacillus in the intestinal tract
NZ750450B2 (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
Pimentel et al. Foods and supplements as probiotic delivery vehicles
Kumar et al. Role of probiotics in health improvement: Adaptations, advantages and their uses
JPWO2023111270A5 (en)